Centessa Pharmaceuticals (CNTA)
(Delayed Data from NSDQ)
$8.60 USD
-0.12 (-1.38%)
Updated May 21, 2024 04:00 PM ET
After-Market: $8.53 -0.07 (-0.81%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Centessa Pharmaceuticals PLC Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 257 | 394 | 595 | 7 | -99,999 |
Receivables | 38 | 24 | 15 | 3 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 21 | 20 | 18 | 1 | NA |
Total Current Assets | 315 | 438 | 629 | 11 | NA |
Net Property & Equipment | 1 | 1 | 0 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 30 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 3 | 5 | 1 | 0 | NA |
Total Assets | 360 | 444 | 630 | 12 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 12 | 14 | 8 | 1 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 28 | 25 | 17 | 1 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 39 | 38 | 25 | 9 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 76 | 70 | 76 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 38 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 124 | 108 | 138 | 9 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 26 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 987 | 939 | 876 | 0 | NA |
Retained Earnings | -753 | -602 | -386 | 0 | NA |
Other Equity | 1 | -2 | 1 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 236 | 336 | 492 | -22 | NA |
Total Liabilities & Shareholder's Equity | 360 | 444 | 630 | 12 | NA |
Total Common Equity | 236 | 336 | 492 | -48 | 0 |
Shares Outstanding | 97.63 | 94.60 | 89.90 | NA | NA |
Book Value Per Share | 2.42 | 3.55 | 5.47 | 0.00 | 0.00 |
Fiscal Year End for Centessa Pharmaceuticals PLC Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 230 | 257 | 281 | 304 | 346 |
Receivables | 36 | 38 | 28 | 27 | 20 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 18 | 21 | 23 | 20 | 18 |
Total Current Assets | 284 | 315 | 332 | 350 | 384 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 29 | 30 | 30 | 27 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 3 | 2 | 2 | 6 |
Total Assets | 328 | 360 | 377 | 393 | 404 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 12 | 11 | 11 | 14 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 20 | 28 | 24 | 23 | 15 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 27 | 39 | 35 | 34 | 30 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 77 | 76 | 74 | 73 | 72 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 113 | 124 | 118 | 116 | 111 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,004 | 987 | 974 | 953 | 946 |
Retained Earnings | -791 | -753 | -716 | -677 | -653 |
Other Equity | 2 | 1 | 1 | 1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 215 | 236 | 259 | 277 | 293 |
Total Liabilities & Shareholder's Equity | 328 | 360 | 377 | 393 | 404 |
Total Common Equity | 215 | 236 | 259 | 277 | 293 |
Shares Outstanding | 100.74 | 97.63 | 97.40 | 95.60 | 94.60 |
Book Value Per Share | 2.14 | 2.42 | 2.66 | 2.89 | 3.10 |